Skip to main content
Devonian Health Group Inc logo

Devonian Health Group Inc — Investor Relations & Filings

Ticker · GSD ISIN · CA2518341078 TSXV Manufacturing
Open in API
Filings indexed 598 across all filing types
Latest filing 2023-06-22 Merger & Acquisition
Country CA Canada
Listing TSXV GSD

About Devonian Health Group Inc

https://groupedevonian.com/

Devonian Health Group Inc. is a clinical-stage botanical pharmaceutical company specializing in the development of novel prescription therapeutic solutions for unmet medical needs. The core business involves late-stage prescription botanical drugs targeting fibroinflammatory autoimmune diseases, with a focus on gastrointestinal, dermatological, and hepatologic conditions. The company utilizes a broad-based technology platform, originating from over 20 years of research, to develop therapies that target multiple cellular pathways and regulate genes linked to these diseases. Its pipeline includes the lead product candidate, Thykamine, currently in Phase 3 clinical trials. Devonian also develops high-value dermatological products alongside its core drug development activities.

Recent filings

Filing Released Lang Actions
Other material contract(s).pdf
Merger & Acquisition Classification · 95% confidence The document is a legal agreement involving representations, warranties, and general provisions related to the transfer of shares and assets between two companies. It includes signatures and schedules detailing assets transferred. There is no indication of financial statements, audit information, regulatory filings, or announcements. The content is consistent with a legal contract related to a transaction, likely a merger, acquisition, or asset transfer. Therefore, the most appropriate classification is Merger & Acquisition (MA). The document length is short and does not appear to be an announcement or a report publication notice, but the actual agreement text.
2023-06-22 English
Other material contract(s).pdf
Legal Proceedings Report Classification · 95% confidence The document is an Assignment Agreement and a Sub-Licensing Agreement between pharmaceutical companies regarding rights and obligations related to a product license and supply. It is a legal contract detailing terms of assignment, sublicensing, royalties, confidentiality, and dispute resolution. There is no indication of financial performance data, regulatory filings, management changes, earnings, or investor presentations. The document is a legal agreement related to intellectual property and commercial rights, not a financial or regulatory report. Therefore, it fits best under Legal Proceedings Report (LTR) as it pertains to legal contractual arrangements and rights assignments between parties.
2023-06-22 English
Non-issuer's submission to jurisdiction and appointment of agent.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'NON-ISSUER FORM OF SUBMISSION TO JURISDICTION AND APPOINTMENT OF AGENT FOR SERVICE OF PROCESS' and contains details about the appointment of an agent for service of process related to securities distribution under a prospectus dated June 22, 2023. It is a legal procedural filing concerning jurisdiction and service of process, not a financial report, earnings release, or management information. The document is relatively short (3703 characters) and does not contain financial data or report content. It is not an announcement of a report but a legal filing related to regulatory compliance. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory documents that do not fit other specific categories.
2023-06-22 English
Other material contract(s).pdf
Regulatory Filings Classification · 95% confidence The document is a detailed legal agreement titled 'Sub-licensing Agreement' dated July 30, 2014, between pharmaceutical companies regarding licensing and supply of a pharmaceutical product. It contains contractual terms, rights, obligations, confidentiality clauses, and signatures of authorized officers. There are no financial statements, regulatory filings, or report-type content such as annual or quarterly reports, earnings releases, or governance disclosures. The document is a contract related to licensing and supply, which does not fit into any of the financial or regulatory report categories. It is not an announcement or a brief notice but a full legal agreement. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous filings that do not fit other categories.
2023-06-22 English
News release - French.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Groupe Santé Devonian has received a US patent allowance notice for a method of treating inflammatory bowel diseases. It discusses the patent, the company's products, and its business focus. There is no financial data, no mention of financial results, no regulatory filings related to financial performance, no management or board changes, no voting results, no capital or financing updates, and no legal proceedings. The document is an announcement of a patent authorization, which is a regulatory or corporate news announcement but does not fit into any of the specific financial or governance report categories. It is not a report itself but an announcement of a corporate event. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2023-06-20 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Devonian Health Group has received a Notice of Allowance for a U.S. patent related to a method of treatment for inflammatory bowel disease. It discusses the patent application, the company's products, and forward-looking statements. There is no financial data, no regulatory filing references, no meeting or voting information, no management or board changes, no earnings or capital updates, and no legal proceedings. The content is primarily a corporate announcement about intellectual property and product development. This type of document does not fit into any of the specific financial or regulatory filing categories but is a general corporate announcement. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous filings that do not fit other categories. The document length is about 5009 characters, which is sufficient to be a full announcement rather than a brief notice or report publication announcement. Confidence in this classification is high due to the clear nature of the content and absence of financial or regulatory report data.
2023-06-20 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.